*de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.* Lancet Oncol *2019; **20:** 1273--85*---In this Article, data (hazard ratios, 95% CIs, and p values) in the following sentence on p 1279 have been corrected: "In women with stage I--II disease, 5-year overall survival was 83·8% (95% CI 78·4--89·5) with chemoradiotherapy versus 82·0% (95% CI 76·5--87·7) with radiotherapy alone (HR 0·84 \[95% CI 0·52--1·38\]; p=0·50), and 5-year failure-free survival was 81·3% (95% CI 74·7--86·3) with chemoradiotherapy versus 77·3% (95% CI 70·5--82·7) with radiotherapy alone (HR 0·87 \[95% CI 0·56--1·36\] p=0·54; appendix p 8)." On p 1282, the same data (hazard ratios and 95% CIs) in the following sentence have also been corrected: "For women with stage I--II endometrial cancer, combined adjuvant treatment yielded only a small absolute improvement of 2% (HR 0·84; 95% CI 0·52--1·38) in 5-year overall survival and of 4% (0·87; 0·56--1·36) in failure-free survival." These corrections have been made to the online version as of Sept 2, 2019, and the printed version is correct.
